A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

Start Date01 Jan 2030

Sponsor / Collaborator

Lisata Therapeutics, Inc.

NCT06261359

/ RecruitingPhase 2

A Phase II, Randomized, Double-blind, Multi-center, Placebo-Controlled Study of the Efficacy and Safety of CEND-1 in Combination With Chemotherapy as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.

Start Date19 Mar 2024

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

NCT05712356

/ Active, not recruitingPhase 2

A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment

Start Date24 Aug 2023

Sponsor / Collaborator

Lisata Therapeutics, Inc.

100 Clinical Results associated with Certepetide

100 Translational Medicine associated with Certepetide

100 Patents (Medical) associated with Certepetide

Literatures (Medical) associated with Certepetide

01 Mar 2026·COLLOIDS AND SURFACES B-BIOINTERFACES

Virus like nanoparticles of VLP-BSA-iRGD enhanced mucosal immune response by targeting M cells

Article

Author: Tan, Huirong ; Tang, Mingrun ; Tu, Zhiwen ; Li, Xuanao ; Wan, Hongping ; Zhao, Xinghong ; Che, Yufeng

In mucosal immunity, targeting microfolds (M)cells of the mucosal epithelium, in combination with suitable adjuvants, is critical for eliciting robust immune response. In the present study, we devised a virus like nanoparticles (VLP)-based nano-delivery platform functionalized with the M cell-targeting peptide iRGD (RGDKGPDC) to enhance the immune responses following intranasal administration. Bovine serum albumin (BSA) was selected as a model antigen, and both BSA and iRGD were conjugated to the VLP surface, forming VLP-BSA-iRGD nanoparticles. Leveraging its M cell-targeting capability, VLP-BSA-iRGD demonstrated enhanced uptake by dendritic cells (DCs) and improved trafficking to lymph nodes compared to BSA alone in a mouse model. VLP-BSA-iRGD enhanced the CCL20 secretion and stimulated the DC activation, as evidenced by an in vitro cell co-culture model. Additionally, it enhanced antigen permeability by disrupting the distribution of the ZO-1 protein in epithelial cells. Importantly, VLP-BSA-iRGD induced stronger humoral and cellular immune responses, accompanied by the upregulation of TLR2/4 expression and activation of the MYD88/NF-κB signaling pathway in DCs. While BSA served as a proof-of-concept antigen, this platform may be broadly applicable to other protein-based subunit vaccines requiring intranasal administration.

01 Jan 2026·Theranostics

Targeted nanoparticles for placenta-specific drug delivery in pregnant rhesus macaques

Article

Author: Renshall, Lewis ; Schmidt, Jenna K ; Schotzko, Michele L ; Mitzey, Ann M ; Golos, Thaddeus G ; Beards, Frances ; Simmons, Heather A ; Harris, Lynda K ; Al-Mugotir, Mona H ; Basu, Puja ; Keding, Logan T ; Shaw, Sarah A ; Ren, Emily

Rationale: To reduce the risks associated with systemic drug administration in pregnancy and create new therapies for placental dysfunction, we have previously developed targeted liposomes capable of selective delivery of payloads to the placentas of pregnant mice. In this study, we assessed whether these liposomes selectively accumulated in the placentas of nonhuman primates and evaluated the maternal systemic response to liposome infusion. Methods: Liposomes were produced using the thin-film method, decorated with the placental homing peptide CRGDKGPDC (iRGD) or non-targeting peptide ARALPSQRSR (ARA) and loaded with 5(6)carboxyfluorescein. Liposomes were infused intravenously into pregnant rhesus macaques early in gestation, at days 45-64 (iRGD, n = 4; ARA, n = 1) or mid-gestation, at days 84-100 (iRGD, n = 4; ARA, n = 2; term = 165 days). After 24 h, maternal blood and maternal, uteroplacental and fetal tissues were collected for evaluation. Results: Liposome infusions were well tolerated, with no adverse clinical reactions or abnormal placental or fetal pathology. Maternal plasma hormone, cytokine and chemokine levels, and complete blood cell counts remained broadly stable for the duration of the treatment period. iRGD-decorated liposomes accumulated in both placental discs of each animal, varying in intensity and tissue distribution. Limited fluorescence was noted in some sections of maternal liver, spleen, kidney and mesenteric lymph nodes, but no visible signal was observed in other maternal or fetal tissues examined. In contrast, ARA-decorated liposomes exhibited a widespread tissue distribution, with fluorescence observed in the majority of maternal, uteroplacental and fetal tissues examined. Conclusions: This study confirms that iRGD-decorated liposomes selectively accumulate in the rhesus macaque placenta in vivo, but are not transferred to the fetus. Their composition is compatible with short term courses of treatment, indicating that this nanoparticle formulation may be suitable for targeted placental delivery of therapeutic payloads in human pregnancy.

01 Dec 2025·Acta Biomaterialia

A dual-targeted liposomal nanosystem for co-delivery of estrogen receptor β antagonist and disulfiram for the non-hormonal treatment of endometriosis

Article

Author: Xian, Shiyun ; Shuai, Xintao ; Shi, Wen ; Liao, Zhouzhou ; Li, Xiao ; Li, Jinbo ; Zhong, Qiyu ; Huang, Jianyun ; Chen, Shuqin ; Tian, Wanjia

Endometriosis is an estrogen-dependent disease that severely affects the physical and mental health of women of childbearing age. Due to the significant side effects of traditional hormone therapies, non-hormonal treatment strategies are urgently needed. In this study, a targeted liposomal nanosystem (cRGD/iRGD-LP@DP) was developed, co-loaded with the pyroptosis inhibitor disulfiram and the estrogen receptor β (ERβ) antagonist 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP), to synergistically block the positive feedback loop between inflammation and estrogen. By modifying the dual-targeting peptides cRGD and iRGD, the nanocarrier can specifically bind to the integrin αvβ3 receptor, which is highly expressed in the lesions and promote the delivery of drugs to deep tissues with the help of the penetration function of iRGD. In vitro experiments showed that cRGD/iRGD-LP@DP significantly inhibited the proliferation and migration of ectopic endometrial stromal cells and the expression of pyroptosis-related proteins (NLRP3/Caspase-1/GSDMD), and reduced the release of inflammatory factors IL-1β and IL-18. In the mouse model, intraperitoneal injection of this nanomedicine could efficiently accumulate in the ectopic lesions, reducing the volume and weight of the lesions without significantly affecting the normal endometrium and ovarian function. Mechanistically, disulfiram blocks pyroptosis by inhibiting the formation of Gasdermin D pores, while PHTPP inhibits the nuclear translocation of ERβ. The two work synergistically to break the vicious cycle between inflammation and estrogen. In addition, this nanosystem has good biosafety and no hepatotoxicity or nephrotoxicity. This study provides an efficient and targeted non-hormonal treatment platform for endometriosis with potential for clinical translation. STATEMENT OF SIGNIFICANCE: Endometriosis is an estrogen-dependent chronic inflammatory disease, and dual targeting of estrogen and inflammation can effectively inhibit the progression of this disease. However, fibrosis of ectopic lesions impedes drug penetration. Additionally, both the estrogen receptor β antagonist PHTPP and the inflammatory inhibitor disulfiram are lipophilic drugs with limited bioavailability. To address this challenge, researchers have developed a nanomedicine modified with cRGD and iRGD dual-targeting peptides. This nanomedicine can specifically bind to integrin αvβ3 receptors, which are highly expressed in ectopic lesions, allowing for deep penetration into the interior of ectopic lesions, and achieving efficient drug delivery. Results demonstrate that this nanomedicine exerts a favorable therapeutic effect on endometriosis, providing an innovative strategy for the non-hormonal treatment of endometriosis.

100

News (Medical) associated with Certepetide

27 Jan 2026

·www.fiercebiotech.com

Lisata reclaims China rights to solid tumor candidate ahead of acquisition

Qilu is still responsible for finishing a phase 2 study that is testing the candidate in patients with locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma.\n Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead solid tumor candidate from Qilu Pharmaceutical.By bringing home certepetide, a cyclic peptide in midstage development for pancreatic ductal adenocarcinoma, Lisata shareholders are one step closer to snagging an extra $2 per share on top of the $4 per share that Kuva is paying for the New Jersey-based biotech. To finalize that pay bump, Kuva next needs to submit certepetide for approval in any country.Qilu originally licensed certepetide in mainland China, Hong Kong, Macau and Taiwan in February 2021 from Cend Therapeutics, which later became Lisata through a merger with Caladrius Biosciences in 2022. The decision to now tear up the deal was mutual, Lisata said in a Jan. 27 release.“We appreciate the collaboration and the work performed by Qilu with certepetide over the past few years,” Lisata President and CEO David Mazzo, Ph.D., said in the release. “As a result of this mutual termination, Lisata regains the full, exclusive rights to certepetide in the Greater China region.” Qilu is still responsible for finishing a phase 2 study that is testing the candidate in combination with the chemotherapy regimen gemcitabine/nab-paclitaxel in patients with locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma, according to the release.Kuva announced that it is acquiring Lisata on Jan. 21, after extensive prior experience with certepetide through a November 2024 pact to use the molecule with its own NanoMark platform to craft a new class of magnetic resonance tumor-detecting imaging agents.The mutually shredded deal comes on the same day Qilu inked another, offering up to $120 million to Insilico Medicine for artificial intelligence aid in developing new cardiometabolic disease candidates. Insilico will use its Pharma.AI platform to design small molecules for as-of-yet undisclosed targets, after which Jinan, China-based Qilu will take over further development.

AcquisitionPhase 2Drug ApprovalLicense out/inPhase 1

27 Jan 2026

·endpoints.news

AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal

Plus, news about Vial, Skyhawk and Gimv: AstraZeneca stops cardio drug: The UK pharma giant has terminated a Phase 1 of an oral cardio drug candidate called AZD0233, according to an update to the clinical trials database. The drugmaker had paused the study last August due to an “adverse finding in a non-clinical, chronic toxicology study.” At the time, an AstraZeneca spokesperson said the pharma was analyzing the safety findings to “determine next steps.” It has now been axed. The CX3CR1-targeted drug was being positioned as a dilated cardiomyopathy treatment candidate. — Kyle LaHucik Lisata and Qilu dissolve pact: The companies ended a licensing and collaboration agreement for certepetide, an iRGD cyclic peptide candidate. China-based Qilu had teamed up with Cend Therapeutics for up to $225 million in 2021. Lisata then bought Cend in 2022. — Kyle LaHucik Vial cans TL1A study: The San Francisco biotech terminated a Phase 1 trial in healthy adults and patients with ulcerative colitis. The culling came after “interim analysis results indicating the primary pharmacokinetic endpoint was unlikely to be met,”according to an update to the US federal clinical trials database. Vial was testing a half-life extended TL1A monoclonal antibody. TL1A became a hot target in I&I in recent years thanks to a couple of multibillion-dollar deals. The startup last disclosed a $67 million Series B in 2022, when it was focused on clinical trials services. It’s now a clinical-stage biotech, with an siRNA in Phase 1 for obesity . — Kyle LaHucik Skyhawk reveals more Huntington’s data: The company said that, in a nine-month analysis, patients who received the 9 mg dose of SKY-0515 saw an average reduction in mHTT protein in blood of 62%. That figure remains unchanged from the company’s six-month update last September. A pooled analysis of patients who received either of the tested doses showed a 0.64-point improvement on a clinical scale for Huntington’s symptoms after nine months, compared with a 0.73-point worsening in historical controls. — Max Gelman European VC firm shutters life science efforts: Gimv said it would not make “any further new investments” in the life sciences. Such companies in its current portfolio, of which Gimv says it has 11, will be “retained.” It’s a reversal from the firm’s 2022 efforts to double the number of its life sciences investments to 20 companies. — Max Gelman

Phase 1License out/inClinical Result

27 Jan 2026

·ir.lisata.com

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu”). The original agreement, negotiated and implemented with CEND Therapeutics and assumed by Lisata as part of its acquisition of CEND Therapeutics in 2022, granted Qilu exclusive rights to develop and commercialize certepetide, Lisata's proprietary iRGD cyclic peptide product candidate, in the Greater China region including Mainland China, Hong Kong, Macau, and Taiwan. This action results in all licenses and other rights granted to Qilu reverting to Lisata. “We appreciate the collaboration and the work performed by Qilu with certepetide over the past few years. As a result of this mutual termination, Lisata regains the full, exclusive rights to certepetide in the Greater China region,” stated David J. Mazzo, PhD, President and Chief Executive Officer of Lisata Therapeutics. Notwithstanding, Qilu maintains its obligations, regulatorily or otherwise, to complete and wind down their ongoing Phase 2 clinical study (NCT06261359) evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma. Lisata has agreed to negotiate with Qilu the potential licensing of relevant study data from this trial, as appropriate. About Certepetide Certepetide (formerly LSTA1), an internalizing RGD (arginyl-glycyl-aspartic acid or iRGD), cyclic peptide product candidate, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor. Certepetide also has been shown to modify the tumor microenvironment resulting in tumors which are more susceptible to immunotherapies. Lisata and its collaborators have amassed significant clinical and non-clinical data demonstrating enhanced efficacy and acceptable safety of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies, RNA-based therapeutics, and Antibody-Drug Conjugates in solid tumor models. To date, certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials designed to test its ability to enhance the effectiveness of standard-of-care chemotherapy for pancreatic cancer. Lisata is exploring the potential of certepetide to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Certepetide has been awarded Fast Track designation (U.S.) and Orphan Drug Designation for pancreatic cancer (U.S. and E.U.) as well as Orphan Drug Designation for glioma (U.S.) and osteosarcoma (U.S.). Additionally, certepetide has received Rare Pediatric Disease Designation for osteosarcoma (U.S.). About Lisata Therapeutics Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the first quarter of 2027, encompassing anticipated data milestones from its ongoing clinical trials. For a comprehensive overview of certepetide's mechanism of action, please view our informative short film. For more information on the Company, please visit www.lisata.com. Forward-Looking Statements This communication contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding the Company’s clinical development programs are forward-looking statements. In addition, when or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Lisata or its management, may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, the potential efficacy of certepetide as a treatment for patients with solid tumors; our beliefs about the potential uses and benefits of certepetide; our ability to secure a partner for the worldwide rights to certepetide or for rights in the Greater China region; the expected expiration of our patents for certepetide; our ability to obtain patent term extension on our U.S. composition of matter patent; statements relating to Lisata’s continued listing on the Nasdaq Capital Market; expectations regarding the capitalization, resources and ownership structure of Lisata; the approach Lisata is taking to discover and develop novel therapeutics; the adequacy of Lisata’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; and the difficulty in predicting the time and cost of development of Lisata’s product candidates. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: results observed from preliminary data are not necessarily indicative of final results and one or more of the clinical outcomes may materially change following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the safety and efficacy of Lisata’s product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in Lisata’s clinical programs, Lisata’s ability to finance its operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of Lisata’s scientific studies, Lisata’s ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in Lisata’s markets, the ability of Lisata to protect its intellectual property rights; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Lisata’s Annual Report on Form 10-K filed with the SEC on February 27, 2025, and in other documents filed by Lisata with the Securities and Exchange Commission. Except as required by applicable law, Lisata undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events, or otherwise. Contact: Media and Investors: Lisata Therapeutics John Menditto Vice President, Investor Relations and Corporate Communications Phone: 908-842-0084 Email: jmenditto@lisata.com

License out/inOrphan DrugFast TrackImmunotherapy

100 Deals associated with Certepetide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Pancreatic Cancer	Phase 2	-	Lisata Therapeutics, Inc.	01 Jan 2030
Pancreatic Adenoma	Phase 2	-	Lisata Therapeutics, Inc.	01 Jan 2030
Pancreatic carcinoma non-resectable	Phase 2	-	Lisata Therapeutics, Inc.	01 Jan 2030
Pancreatic Cancer	Phase 2	United States	Lisata Therapeutics, Inc.	13 Jun 2024
Glioblastoma Multiforme	Phase 2	Estonia	Lisata Therapeutics, Inc.	17 Jan 2024
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	China	Qilu Pharmaceutical Co., Ltd.	21 Oct 2021
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	China	Cend Therapeutics, Inc.	21 Oct 2021
Appendiceal Neoplasms	Phase 2	United States	University of Kansas Medical Center	20 Oct 2021
Colonic Cancer	Phase 2	United States	University of Kansas Medical Center	20 Oct 2021
Colorectal Cancer	Phase 2	United States	Cend Therapeutics, Inc.	20 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05121038 (CENDIFOX, Company_Website) Manual	Phase 1/2	Pancreatic Ductal Adenocarcinoma Neoadjuvant	35	Certepetide + mFOLFIRINOX	psivlklsue(ppbemhffhv) = tdwrtvkedi tlhlkfbjft (kxlmhoilfg ) View more	Positive	29 Sep 2025
iLSTA (ESMO_GI2025 \| Company_Website) Manual	Phase 1/2	Advanced Pancreatic Ductal Adenocarcinoma First line	30	GemcitabineGemcitabine + nab-paclitaxel + LSTA-1 + Durvalumab OR gemcitabine + nab-paclitaxel+placebo LSTA-1+ placebo durvalumab OR gemcitabinedurvalumab OR gemcitabine+ nab-paclitaxel+ activeo LSTA-1+placebo LSTA-1LSTA-1+ placebo durvalumab	axabjbwxae(vwvyioauuf) = egchkkqgiv heauxbydxb (gfnbfxbeje ) View more	Positive	03 Jul 2025
				gemcitabine+ nab-paclitaxel+ activeo LSTA-1+placebo LSTA-1LSTA-1+ placebo durvalumab (Cohort 2)	dmfnzozmqt(sidxohqdlc) = zoyllpoivf ccfmchwxwj (zztpdfgwck )
NCT05042128 (ASCEND, ESMO_GI2025)	Phase 2	Metastatic Pancreatic Ductal Adenocarcinoma First line	63	Certepetide (CERT)	llorekjqqt(apgonckfvh) = ksiaheyawy ukypsnvobg (lzzohdznpg ) View more	Positive	02 Jul 2025
				Placebo (PLA)	llorekjqqt(apgonckfvh) = rsljewfilf ukypsnvobg (lzzohdznpg ) View more
NCT05042128 (AGITG ASCEND, ASCO_GI2025)	Phase 2	Metastatic Pancreatic Ductal Adenocarcinoma First line	95	Certepetide + Gemcitabine/Nab-paclitaxel	vlngwdguse(gbvblkyxgt) = mldwiwmbbe vkdmiegrzl (hgqgdiedrf, 36.4% - 60.5%) View more	Positive	23 Jan 2025
				Placebo + Gemcitabine/Nab-paclitaxel	vlngwdguse(gbvblkyxgt) = gfldyqcxnc vkdmiegrzl (hgqgdiedrf, 22.6% - 58.3%) View more
ACTRN12623000223639 (ASCO_GI2025)	Not Applicable	Advanced Pancreatic Ductal Adenocarcinoma	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	nyphknorec(oykymrfqqv) = myqmlgpdxh hsfedcmldg (eymhmuqgot )	Positive	23 Jan 2025
NCT05052567 (ASCO 12023 \| ASCO 22023) Manual	Phase 1/2	Metastatic Pancreatic Ductal Adenocarcinoma	38	CEND-1+gemcitabine+nab-paclitaxel (CEND-1 1.6 mg/kg)	qkbgnbscjh(kjrltorpcm) = kshbddcftw mokqsxniuf (qnvagzxepd, 0.59 - NE) View more	Positive	26 May 2023
				CEND-1+gemcitabine+nab-paclitaxel (CEND-1 3.2 mg/kg)	qkbgnbscjh(kjrltorpcm) = tcvqemowgv mokqsxniuf (qnvagzxepd, 3.25 - 7.46) View more
ACTRN12618000804280 \| NCT03517176 (Literature \| Pubmed \| Lancet Gastroenterol Hepatol) Manual	Phase 1	Metastatic Pancreatic Ductal Adenocarcinoma	31	nab-paclitaxel+gemcitabine+CEND-1 (dose-escalation)	knpitxzgtw(wilayprazl) = rzclljhqjb xazymcnerx (rhwutlfmwp ) View more	Positive	05 Jul 2022
NCT03517176 (ESMO2020)	Phase 1	Metastatic Pancreatic Cancer	29	CEND-1 + nab-paclitaxel + gemcitabine	imblahswfu(wtcvfrdimt) = hgbaptyedy rawvemrrwo (ncyolxkvbo ) View more	Positive	17 Sep 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis